About us

Strategy

Ecrins Therapeutics' business strategy involves building a strong intellectual property portfolio with proprietary or licensed-in anti-cancer compounds.

Our discovery of novel molecules with anti-tumor properties was made possible through an innovative approach in phenotypic screening and subsequent confirmation of anti-cancer activity in cancer xenograft models. Ecrins Therapeutics uses propriety technologies to build a large and diversified product portfolio that it intends to develop and commercialize through licensing agreements with pharmaceutical companies, through joint development and through internal product development programs.

Products

Ecrins Therapeutics is developing a wide-ranging portfolio of anti-cancer products. Our compounds target tumors by several different mechanisms and are intended for the treatment of a range of cancers. In particular, Ecrins Therapeutics’s pipeline includes small molecule inhibitors that target tumor vessels, effectively starving off cancer cells.

Read more →

Created in 2010 with the support of the “Grenoble Alpes Incubation” (“GRAIN”) business incubator, Ecrins Therapeutics is a spin-off from the Grenoble Institute of Neurosciences and Joseph Fourier University. A prize winner of the 2009 and 2010 National Innovation Contest MENRT/ANVAR “Emergence” and “Création-Développement” Grants, the team of Ecrins Therapeutics pursues the pre-clinical and clinical development of new candidate anti-cancer medicines. The company was founded by Drs. Aurélie Juhem and Andrei Popov, supported by Prof. François Berger of the University Joseph Fourier, and the Grenoble University Hospital. Prior to the creation of start-up, the project was awarded the grant “Proof of concept” by the Lyon Auvergne Rhône-Alpes Cancéropôle (CLARA).

Read more →